Table 1.
Clinical-demographic characteristics of the MS population included (n = 114).
| Median | (range) | |
|---|---|---|
| Age, years | 42 | (21 – 73) |
| Disease duration, years | 10 | (0 – 38) |
| Treatment duration since first DMT, years | 8 | (0 – 25) |
| Number of previous DMTs | 1 | (0 – 5) |
| EDSS | 1.5 | (0 – 7.5) |
| Number | (%) | |
| Gender, female | 80 | (70%) |
| MS form, RR | 103 | (90%) |
| MS form, SP | 11 | (8%) |
| On treatment | 106 | (93%) |
| Treatment with second line DMTs | 80 | (70%) |
| Treatment with depletive DMTs a | 37 | (32%) |
a
Depletive DMTs include all the following: rituximab, ocrelizumab, alemtuzumab, cladribine.
DMTs, disease-modifying treatments; EDSS, expanded disability status scale; MS, multiple sclerosis; RR, relapsing-remitting; SP, secondary progressive.